Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    11796852 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Suspended Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
Condition: Urticaria
Intervention: Drug: Rituximab
2 Completed Effect of Anti-IgE in Chronic Urticaria
Condition: Urticaria
Intervention: Drug: Xolair® (Omalizumab)

Indicates status has not been verified in more than two years